HOOKIPA Pharma Inc.
HOOK · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.07 | 0.01 | -0.03 |
| FCF Yield | -306.20% | -80.56% | -47.14% | -102.74% |
| EV / EBITDA | 0.33 | 0.44 | 0.89 | -0.30 |
| Quality | ||||
| ROIC | -87.01% | -80.37% | -53.16% | -79.38% |
| Gross Margin | 93.74% | 82.35% | 74.72% | 74.85% |
| Cash Conversion Ratio | 1.77 | 0.71 | 0.31 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 45.56% | 2.95% | -10.06% | 15.60% |
| Free Cash Flow Growth | -25.11% | -146.59% | 68.17% | -88.44% |
| Safety | ||||
| Net Debt / EBITDA | 0.95 | 1.43 | 1.77 | 0.79 |
| Interest Coverage | -25,727.50 | -308.18 | -106.48 | -90.95 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -8.60 | -0.33 |
| Cash Conversion Cycle | -955.15 | -934.84 | -34.72 | -1,393.09 |